DR-310 Clinical actionability for and heritable factors involved in glioblastoma

This project aims to use whole genome sequencing data to 1) describe the driver landscape of glioblastoma, 2) determine potential actionability with registered and experimental targeted drugs and therapies, and 3) quantify and characterize the contribution of germline variation to the development of glioblastoma. This information will guide clinicians in patient education and diagnostics and be supportive for the GLOW clinical study that was recently started and which will investigate the potential added value of WGS-based diagnostics for patients with recurrent resectable glioblastoma.

Mark van Opijnen, Haaglanden Medisch Centrum, the Netherlands